 ADMA Biologics recently reported a mixed Q42020 earnings with a slight miss on EPS and a slight beat on revenue. Consequently, ADMA has been under substantial selling pressure. The ongoing pandemic has disrupted the industry; however, ADMA was able to report record revenue and expects to report quarter-over-quarter revenue growth. 